Dai­ichi Sankyo shakes up its R&D lead­er­ship, dis­patch­ing Ju­nichi Ko­ga to the US to run glob­al ops

Two years af­ter bring­ing out the bud­get ax and shak­ing up its glob­al R&D group, Dai­ichi Sankyo is re­vamp­ing the lead­er­ship of its re­search arm and shift­ing the cen­ter of grav­i­ty to the US. They’re al­so sharp­en­ing their fo­cus on on­col­o­gy at a time the pur­suit of new can­cer drugs has gripped most of the ma­jors.

Out: Glenn Gorm­ley, who took the R&D reins at Dai­ichi Sankyo in 2011 af­ter a 20-year run at three big phar­ma groups: Mer­ck, As­traZeneca and No­var­tis. He’ll stay on, though, as chair­man of the board and spe­cial ad­vis­er to glob­al CEO Jo­ji Nakaya­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.